met12 Search Results


met12  (MedChemExpress)
94
MedChemExpress met12
( a ) Indirect IF micrographs demonstrating a lack of cell surface TRAIL immunoreactivity in live, non-permeabilized Jurkat cells (left panel) and TRAIL immunoreactivity (green) localized to intracellular vesicles in fixed and permeabilized Jurkat cells (right panel, nuclei stained blue with DAPI). ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h (upper 2 panels, Control) and marked prevention of Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h in the presence of a neutralizing anti-TRAIL antibody (10 μg/mL Jurkat to NB cell ratio: 2 to 1). ( c ) Line graph demonstrating significant prevention of PMA-activated TrkAIII-SH-SY5Y elimination at 6, 12 and 12 h by the neutralizing anti-TRAIL antibody (10 μg/mL) but not by <t>MET12</t> (10 μM) in triplicate experiments, each performed in duplicate (* p < 0.0001).
Met12, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/met12/Met-12/pmc12940949-185-9-26
Average 94 stars, based on 1 article reviews
met12 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
met-12  (TargetMol)
N/A
   Buy from Supplier
met12 fas inhibitor  (ONL Therapeutics)
90
ONL Therapeutics met12 fas inhibitor
( a ) Indirect IF micrographs demonstrating a lack of cell surface TRAIL immunoreactivity in live, non-permeabilized Jurkat cells (left panel) and TRAIL immunoreactivity (green) localized to intracellular vesicles in fixed and permeabilized Jurkat cells (right panel, nuclei stained blue with DAPI). ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h (upper 2 panels, Control) and marked prevention of Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h in the presence of a neutralizing anti-TRAIL antibody (10 μg/mL Jurkat to NB cell ratio: 2 to 1). ( c ) Line graph demonstrating significant prevention of PMA-activated TrkAIII-SH-SY5Y elimination at 6, 12 and 12 h by the neutralizing anti-TRAIL antibody (10 μg/mL) but not by <t>MET12</t> (10 μM) in triplicate experiments, each performed in duplicate (* p < 0.0001).
Met12 Fas Inhibitor, supplied by ONL Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/met12/met12+fas+inhibitor/pm35160044-312-17-21
Average 90 stars, based on 1 article reviews
met12 fas inhibitor - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


( a ) Indirect IF micrographs demonstrating a lack of cell surface TRAIL immunoreactivity in live, non-permeabilized Jurkat cells (left panel) and TRAIL immunoreactivity (green) localized to intracellular vesicles in fixed and permeabilized Jurkat cells (right panel, nuclei stained blue with DAPI). ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h (upper 2 panels, Control) and marked prevention of Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h in the presence of a neutralizing anti-TRAIL antibody (10 μg/mL Jurkat to NB cell ratio: 2 to 1). ( c ) Line graph demonstrating significant prevention of PMA-activated TrkAIII-SH-SY5Y elimination at 6, 12 and 12 h by the neutralizing anti-TRAIL antibody (10 μg/mL) but not by MET12 (10 μM) in triplicate experiments, each performed in duplicate (* p < 0.0001).

Journal: International Journal of Molecular Sciences

Article Title: Jurkat T-Cell Antigen-Independent Elimination of PMA-Activated Neuroblastoma Cells Is Triggered by CCL2/CCR2, Depends Upon Lipid Raft LFA1/ICAM1 Immune Synapses, Is Mediated by m-TRAIL and Is Augmented by the TrkAIII Oncoprotein

doi: 10.3390/ijms27041970

Figure Lengend Snippet: ( a ) Indirect IF micrographs demonstrating a lack of cell surface TRAIL immunoreactivity in live, non-permeabilized Jurkat cells (left panel) and TRAIL immunoreactivity (green) localized to intracellular vesicles in fixed and permeabilized Jurkat cells (right panel, nuclei stained blue with DAPI). ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h (upper 2 panels, Control) and marked prevention of Jurkat elimination of PMA-activated TrkAIII-SH-SY5Y cells at 24 h in the presence of a neutralizing anti-TRAIL antibody (10 μg/mL Jurkat to NB cell ratio: 2 to 1). ( c ) Line graph demonstrating significant prevention of PMA-activated TrkAIII-SH-SY5Y elimination at 6, 12 and 12 h by the neutralizing anti-TRAIL antibody (10 μg/mL) but not by MET12 (10 μM) in triplicate experiments, each performed in duplicate (* p < 0.0001).

Article Snippet: UCF-101, z-VAD-fmk, z-IETD-fmk, z-DEVD-fmk, INCB3284, Capivasertib, NSC-87877, BIRT377, PP1, MET12, soluble recombinant TRAIL (s-TRAIL), recombinant human ICAM-1 (rICAM-1), IT1t-dihydrochloride, Bindarit and recombinant human osteoprotegerin were from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Staining, Control

( a ) Line graph demonstrating that Jurkat cells eliminate PMA-activated (60 ng/mL for 16 h, followed by removal) pcDNA-SH-SY5Y, parental SH-SY5Y and SK-N-SH NB cells with similar kinetics over 24 h, at a 2 to 1 ratio with NB cells. ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated (60 ng/mL for 16 h, followed by removal) SMS-KCNR but not NB-1 or IMR-32 cells, delayed to 48 and 72 h, at a 6 to 1 ratio, plus PMA-activated SMS-KCNR, NB-1 or IMR-32 counterparts in the absence of Jurkat cells for comparison. ( c ) Line graphs demonstrating significant Jurkat elimination of PMA-activated (60 ng/mL for 16 h, followed by removal) SMS-KCNR but not -NB-1 or IMR-32 cells by Jurkat cells at a 6 to 1 ratio, with respect to the fold increase in PMA-activated SMS-KCNR, NB-1 and IMR-32 numbers in the absence of Jurkat cells, in duplicate experiments performed in duplicate (* p < 0.0001). ( d ) RT-PCRs demonstrating marked induction of SMS-KCNR but not NB-1 or IMR-32 CCL2 mRNA expression, compared to 18S rRNA levels, following PMA treatment (60 ng/mL for 6 h). ( e ) Western blot demonstrating induction of SMS-KCNR CCL2 compared to MMP-2 protein expression in 20× concentrated 48 h-conditioned media from non-activated (Con) and PMA-activated (PMA, 60 ng/mL for 16 h, followed by removal and 48-h serum-free culture) SMS-KCNR cells. ( f ) Western blots demonstrating caspase-3 cleavage in whole cell extracts (30 μg loads) of Jurkat cells isolated following a 24 h interaction with non-activated pcDNA-SH-SY5Y, TrkAIII-SH-SY5Y, IMR-32 and SMS-KCNR cells at a 4 to 1 ratio with NB cells, and the prevention of caspase-3 cleavage in Jurkat cells isolated after a 24 h interaction with IMR-32 or SMS-KCN cells in the presence of MET12 (10 μM).

Journal: International Journal of Molecular Sciences

Article Title: Jurkat T-Cell Antigen-Independent Elimination of PMA-Activated Neuroblastoma Cells Is Triggered by CCL2/CCR2, Depends Upon Lipid Raft LFA1/ICAM1 Immune Synapses, Is Mediated by m-TRAIL and Is Augmented by the TrkAIII Oncoprotein

doi: 10.3390/ijms27041970

Figure Lengend Snippet: ( a ) Line graph demonstrating that Jurkat cells eliminate PMA-activated (60 ng/mL for 16 h, followed by removal) pcDNA-SH-SY5Y, parental SH-SY5Y and SK-N-SH NB cells with similar kinetics over 24 h, at a 2 to 1 ratio with NB cells. ( b ) Representative micrographs demonstrating Jurkat elimination of PMA-activated (60 ng/mL for 16 h, followed by removal) SMS-KCNR but not NB-1 or IMR-32 cells, delayed to 48 and 72 h, at a 6 to 1 ratio, plus PMA-activated SMS-KCNR, NB-1 or IMR-32 counterparts in the absence of Jurkat cells for comparison. ( c ) Line graphs demonstrating significant Jurkat elimination of PMA-activated (60 ng/mL for 16 h, followed by removal) SMS-KCNR but not -NB-1 or IMR-32 cells by Jurkat cells at a 6 to 1 ratio, with respect to the fold increase in PMA-activated SMS-KCNR, NB-1 and IMR-32 numbers in the absence of Jurkat cells, in duplicate experiments performed in duplicate (* p < 0.0001). ( d ) RT-PCRs demonstrating marked induction of SMS-KCNR but not NB-1 or IMR-32 CCL2 mRNA expression, compared to 18S rRNA levels, following PMA treatment (60 ng/mL for 6 h). ( e ) Western blot demonstrating induction of SMS-KCNR CCL2 compared to MMP-2 protein expression in 20× concentrated 48 h-conditioned media from non-activated (Con) and PMA-activated (PMA, 60 ng/mL for 16 h, followed by removal and 48-h serum-free culture) SMS-KCNR cells. ( f ) Western blots demonstrating caspase-3 cleavage in whole cell extracts (30 μg loads) of Jurkat cells isolated following a 24 h interaction with non-activated pcDNA-SH-SY5Y, TrkAIII-SH-SY5Y, IMR-32 and SMS-KCNR cells at a 4 to 1 ratio with NB cells, and the prevention of caspase-3 cleavage in Jurkat cells isolated after a 24 h interaction with IMR-32 or SMS-KCN cells in the presence of MET12 (10 μM).

Article Snippet: UCF-101, z-VAD-fmk, z-IETD-fmk, z-DEVD-fmk, INCB3284, Capivasertib, NSC-87877, BIRT377, PP1, MET12, soluble recombinant TRAIL (s-TRAIL), recombinant human ICAM-1 (rICAM-1), IT1t-dihydrochloride, Bindarit and recombinant human osteoprotegerin were from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Comparison, Expressing, Western Blot, Isolation